A Phase 2, Randomized, Parallel Group, Dose-Finding, Multicenter, Multinational Study of the Safety, Tolerability and Pilot Efficacy of Three Blinded Doses of the Oral Factor Xa Inhibitor Betrixaban Compared With Open-Label Dose-Adjusted Warfarin in Patients With Non-Valvular Atrial Fibrillation (EXPLORE Xa)

Trial Profile

A Phase 2, Randomized, Parallel Group, Dose-Finding, Multicenter, Multinational Study of the Safety, Tolerability and Pilot Efficacy of Three Blinded Doses of the Oral Factor Xa Inhibitor Betrixaban Compared With Open-Label Dose-Adjusted Warfarin in Patients With Non-Valvular Atrial Fibrillation (EXPLORE Xa)

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Sep 2017

At a glance

  • Drugs Betrixaban (Primary) ; Warfarin
  • Indications Stroke; Thrombosis
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms EXPLORE-Xa
  • Most Recent Events

    • 21 Apr 2012 New source identified and integrated (European Clinical Trials Database: EudraCT2008-005977-37).
    • 29 Aug 2010 Pharmacodynamic results were presented at ESC Congress 2010: Annual Congress of the European Society of Cardiology.
    • 29 Aug 2010 Additional pharmacodynamic results will be presented at the European Society of Cardiology (ECS) Congress in Stockholm, according to a Protola Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top